VCEL earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E 103.87. Updated 2026-07-23.
Vericel (VCEL) Research Hub
Vericel (VCEL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 38.34 USD (-1.67%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 103.87, market cap 2.29B. This hub links to the full technical, earnings and options research available for VCEL.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 38.34 USD (-1.67%) |
| 52-week range | 37.21 USD – 49.32 USD |
| Trend regime | Range |
| 14-day RSI | 8.9 (Oversold) |
| Trailing P/E | 103.87 |
| Market cap | 2.29B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for VCEL
Covered Call on VCEL: how it works, illustrative setup around the real 38.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VCEL: how it works, illustrative setup around the real 38.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VCEL: how it works, illustrative setup around the real 38.34 USD price, max profit/loss, breakeven and when to use it. Educational.
VCEL technical analysis: range, last 38.34 USD, RSI 8.9, 52w range 37.21 USD–49.32 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is VCEL in?
Vericel (VCEL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VCEL in an uptrend or downtrend?
As of 2026-09-11, VCEL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VCEL's trailing P/E ratio?
VCEL's trailing P/E is 103.87, with a market cap of 2.29B. See the earnings research page for full valuation detail.
When does VCEL next report earnings?
VCEL is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.04 USD.